Literature DB >> 29474241

Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels: Clinical Implications.

Mark Spitzer1, Nathan P Wiederhold1.   

Abstract

OBJECTIVE: The aims of the study were to assess for differences in antifungal in vitro potency at pH 7 and pH 4 and to discuss any potential clinical implications of that difference.
MATERIALS AND METHODS: A retrospective analysis of 217 first positive yeast cultures from 217 patients. Yeast isolates underwent antifungal susceptibility testing, with minimum inhibitory concentrations (MICs) (microgram per milliliter) measured at pH 7 and pH 4 for fluconazole, itraconazole, miconazole, clotrimazole, terconazole, and nystatin. Only the first isolates collected from each patient were included in the analysis.
RESULTS: Yeast first isolates included 173 Candida albicans, 15 Candida glabrata, and 29 isolates from 8 other species. Geometric mean (GM) MIC values for all antifungals were significantly higher when tested at pH 4 (p < .001 for all comparisons). For C. albicans, the largest GM MIC differences were observed for terconazole (0.17 pH 7 vs 6.17 pH 4) and clotrimazole (0.04 vs 0.24). For terconazole, 97.7% of the isolates had a MIC of 1 or less at pH 7 but 83.2% had a MIC of 4 or higher at pH 4. For C. glabrata, terconazole (GM MIC = 0.26 pH 7 vs >64 pH 4), clotrimazole (0.13 vs 6.96), miconazole (0.06 vs 0.76), and fluconazole (3.17 vs 26.6) were most affected. All C. glabrata isolates had a MIC of 1 or less for terconazole at pH 7 and one had a MIC of 8 at pH 4, whereas all the rest were highly resistant (MIC > 64).
CONCLUSIONS: Antifungals have reduced in vitro potency when tested at lower pH. Candida glabrata is more affected than C. albicans. The impact may be greatest for the antifungal terconazole and against C. glabrata isolates.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29474241     DOI: 10.1097/LGT.0000000000000383

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  6 in total

1.  Determining Susceptibility in Candida Vaginal Isolates.

Authors:  Jack D Sobel; Robert Akins
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

2.  A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.

Authors:  E L Larkin; L Long; N Isham; K Borroto-Esoda; S Barat; D Angulo; S Wring; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

Authors:  R Sobel; P Nyirjesy; M A Ghannoum; D A Delchev; N E Azie; D Angulo; I A Harriott; K Borroto-Esoda; J D Sobel
Journal:  BJOG       Date:  2021-11-08       Impact factor: 7.331

4.  Topical Treatment of Recurrent Vulvovaginal Candidiasis: An Expert Consensus.

Authors:  Nancy A Phillips; Gloria Bachmann; Hope Haefner; Mark Martens; Colleen Stockdale
Journal:  Womens Health Rep (New Rochelle)       Date:  2022-01-31

Review 5.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

6.  In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis.

Authors:  Jack D Sobel; Katyna Borroto-Esoda; Nkechi Azie; David Angulo
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.